ReviewFrontiers in cardiovascular medicine2026
Methylation-centric epigenetic regulation in dilated cardiomyopathy: mechanisms, metabolic interplay, and translational potential.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dilated cardiomyopathy (DCM) is one of the main causes of heart failure and heart transplantation, with complex causes involving multiple factors such as genetics, epigenetics, and environment. In recent years, methylation, as a key epigenetic regulatory approach, has increasingly garnered attention for its role in the mechanisms of DCM onset. This review comprehensively summarizes the mechanisms, functions, and metabolic regulatory characteristics of DNA methylation, histone methylation, and RNA N6-methyladenosine (m6A) modification in the occurrence and development of DCM. Literature was selected from PubMed and Web of Science, focusing on studies related to methylation and DCM published in recent years, as well as comprehensive and well-structured review articles. Studies have shown that these three methylation modifications collectively influence the phenotypic characteristics of DCM by regulating processes such as gene expression, metabolic homeostasis, inflammatory responses, fibrosis, and cell death in cardiomyocytes. Moreover, there is cross-regulation among these modifications, which is closely related to carbon metabolism and the tricarboxylic acid cycle. Further exploration of methylation regulatory mechanisms not only helps reveal the underlying basis of DCM but also opens new directions for targeted therapy and precision medicine. This article aims to summarize existing research advancements, explore the clinical translation potential of methylation-related mechanisms, and identify key questions and challenges for future studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.